Personalized HLA-aware TCR measure predicts the risk of symptomatic SARS-CoV-2 infection following booster vaccination

HLA-driven heterogeneity and limitations of live T cell functional assays routinely thwart assessment of cell-mediated immunity in vaccination trials. To address this, we developed a T-cell receptor (TCR)-based measure of immunogen recognition and evaluated it in COV-BOOST, a third-dose COVID-19 vaccine trial, during the Delta and Omicron waves (2021-2022, United Kingdom). We estimated HLA-aware Spike-reactive T cell (HA-TS) breadth from participant HLA genotypes, TCRβ repertoires, and a novel SARS-CoV-2 S HLA-linked reference catalog. Higher post-boost HA-TS breadth was associated with lower symptomatic infection risk (HR 0.58, 95% CI 0.39-0.86). This association persisted after adjustment for neutralizing antibody titers and IFN-γ responses. Examination of HA-TS across prior studies showed that it reflects participant genotype, exposure intensity, and time from exposure to sampling. These findings highlight the possibility that estimates of antigen-specific T cell repertoire breadth could serve as a correlate of protection to accelerate vaccine development.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-12
DOI
https://doi.org/10.64898/2026.11.10.26367219
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Personalized HLA-aware TCR measure predicts the risk of symptomatic SARS-CoV-2 infection following booster vaccination

Teresa Lambe, Emily S. Ford, Andrew J. Fiore-Gartland, Alasdair Peter Stuart Munro et al.
medRxiv
SARS-CoV-2 and COVID-19 Research
preprint

Personalized HLA-aware TCR measure predicts the risk of symptomatic SARS-CoV-2 infection following booster vaccination

Teresa Lambe, Emily S. Ford, Andrew J. Fiore-Gartland, Alasdair Peter Stuart Munro, Narges Ebrahimi, Koshlan Mayer-Blackwell, Jennifer Alderson, Sagida Bibi, Saul N. Faust, Merryn Voysey, Adam P. Dale, Khiyam Hussain, Xinxue Liu
preprint en

Abstract

HLA-driven heterogeneity and limitations of live T cell functional assays routinely thwart assessment of cell-mediated immunity in vaccination trials. To address this, we developed a T-cell receptor (TCR)-based measure of immunogen recognition and evaluated it in COV-BOOST, a third-dose COVID-19 vaccine trial, during the Delta and Omicron waves (2021-2022, United Kingdom). We estimated HLA-aware Spike-reactive T cell (HA-TS) breadth from participant HLA genotypes, TCRβ repertoires, and a novel SARS-CoV-2 S HLA-linked reference catalog. Higher post-boost HA-TS breadth was associated with lower symptomatic infection risk (HR 0.58, 95% CI 0.39-0.86). This association persisted after adjustment for neutralizing antibody titers and IFN-γ responses. Examination of HA-TS across prior studies showed that it reflects participant genotype, exposure intensity, and time from exposure to sampling. These findings highlight the possibility that estimates of antigen-specific T cell repertoire breadth could serve as a correlate of protection to accelerate vaccine development.

medRxiv
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa (ZA), University of Washington (US), University Hospital Southampton NHS Foundation Trust (GB), University of Oxford (GB), Fred Hutch Cancer Center (US), NIHR Southampton Biomedical Research Centre (GB), Oxford BioMedica (United Kingdom) (GB), University of Southampton (GB)
Good health and well-being
SARS-CoV-2 and COVID-19 Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon